John Jordan

Director of Finance/CFO at Rna Diagnostics, Inc.

Health Technology

Profile

John Jordan has held positions as a Chief Financial Officer and Director at Rna Diagnostics, Inc. and as a Director and Chief Financial Officer at Proteocyte Diagnostics, Inc. Currently, Mr. Jordan holds positions at both companies as their Chief Financial Officer and Director.

John Jordan active positions

Companies	Position	Start
Rna Diagnostics, Inc. Rna Diagnostics, Inc. Medical SpecialtiesHealth Technology Rna Diagnostics, Inc. operates as a cancer diagnostics company which builds a platform of prognostic biomarker tools to help improve the lives of patients undergoing chemotherapy. The firm develops prognostic biomarker tools to improve the lives of women undergoing chemotherapy for breast cancer. It provides The RNA Disruption Assay (RDA), which provides physicians with an evaluation of how individual patients are responding to chemotherapy. The company was founded by Kenneth P. H. Pritzker in 2010 and is headquartered in Toronto, Canada.	Director of Finance/CFO	-
Proteocyte Diagnostics, Inc. Proteocyte Diagnostics, Inc. Medical SpecialtiesHealth Technology Proteocyte Diagnostics, Inc. develops prognostic oral precancer laboratory, which objectively and accurately detects oral lesions. The company was founded in 2011 and is headquartered in Toronto, Canada.	Director of Finance/CFO	-

All active positions of John Jordan

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of John Jordan's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Rna Diagnostics, Inc. Rna Diagnostics, Inc. Medical SpecialtiesHealth Technology Rna Diagnostics, Inc. operates as a cancer diagnostics company which builds a platform of prognostic biomarker tools to help improve the lives of patients undergoing chemotherapy. The firm develops prognostic biomarker tools to improve the lives of women undergoing chemotherapy for breast cancer. It provides The RNA Disruption Assay (RDA), which provides physicians with an evaluation of how individual patients are responding to chemotherapy. The company was founded by Kenneth P. H. Pritzker in 2010 and is headquartered in Toronto, Canada.	Health Technology
Proteocyte Diagnostics, Inc. Proteocyte Diagnostics, Inc. Medical SpecialtiesHealth Technology Proteocyte Diagnostics, Inc. develops prognostic oral precancer laboratory, which objectively and accurately detects oral lesions. The company was founded in 2011 and is headquartered in Toronto, Canada.	Health Technology